Editor's Note: Any reference to TheStreet Ratings and its underlying recommendation does not reflect the opinion of TheStreet, Inc. or any of its contributors including Jim Cramer.

Yesterday, April 1, 2015, 62 U.S. common stocks issued filings of shares being bought or sold by insiders. The transactions ranged in value from $332.83 to $21,591,180.00.

Highlighted Stocks Traded by Insiders:

Salesforce.com (CRM) - FREE Research Report

Benioff Marc, who is Chairman of the Board & CEO at Salesforce.com, sold 37,500 shares at $66.69 on April 1, 2015. Following this transaction, the Chairman of the Board & CEO owned 37.9 million shares meaning that the stake was reduced by 0.1% with the 37,500-share transaction.

The shares most recently traded at $66.50, down $0.19, or 0.28% since the insider transaction. Historical insider transactions for Salesforce.com go as follows:

  • 4-Week # shares sold: 217,127
  • 12-Week # shares sold: 681,227
  • 24-Week # shares sold: 1.4 million

The average volume for Salesforce.com has been 4.6 million shares per day over the past 30 days. Salesforce.com has a market cap of $43.5 billion and is part of the technology sector and computer software & services industry. Shares are up 11.41% year-to-date as of the close of trading on Wednesday.

salesforce.com, inc. provides enterprise cloud computing solutions, with a focus on customer relationship management to various businesses and industries worldwide. Currently, there are 25 analysts who rate Salesforce.com a buy, 1 analyst rates it a sell, and 4 rate it a hold.

Exclusive Offer: Get the latest Stock Analysis on CRM - FREE

TheStreet Quant Ratings rates Salesforce.com as a hold. The company's strengths can be seen in multiple areas, such as its robust revenue growth, solid stock price performance and increase in net income. However, as a counter to these strengths, we find that the company has favored debt over equity in the management of its balance sheet. Get the full Salesforce.com Ratings Report from TheStreet Quant Ratings now.

EXCLUSIVE OFFER: See inside Jim Cramer's multi-million dollar charitable trust portfolio to see the stocks he thinks could be potential winners. Click here to see his holdings for 14-days FREE.

Stone Energy (SGY) - FREE Research Report

Welch David H, who is Chairman, President & CEO at Stone Energy, sold 11,000 shares at $14.64 on April 1, 2015. Following this transaction, the Chairman, President & CEO owned 806,627 shares meaning that the stake was reduced by 1.35% with the 11,000-share transaction.

The shares most recently traded at $15.14, up $0.50, or 3.3% since the insider transaction. Historical insider transactions for Stone Energy go as follows:

  • 4-Week # shares bought: 7,000
  • 4-Week # shares sold: 3,000
  • 12-Week # shares bought: 7,000
  • 12-Week # shares sold: 3,000
  • 24-Week # shares bought: 7,000
  • 24-Week # shares sold: 3,000

The average volume for Stone Energy has been 1.3 million shares per day over the past 30 days. Stone Energy has a market cap of $820.9 million and is part of the basic materials sector and energy industry. Shares are down 12.56% year-to-date as of the close of trading on Wednesday.

Stone Energy Corporation, an independent oil and natural gas company, engages in the acquisition, exploration, exploitation, development, and operation of oil and gas properties in the Gulf of Mexico and the Appalachia region. Currently, there are 5 analysts who rate Stone Energy a buy, no analysts rate it a sell, and 2 rate it a hold.

Exclusive Offer: Get the latest Stock Analysis on SGY - FREE

TheStreet Quant Ratings rates Stone Energy as a sell. The company's weaknesses can be seen in multiple areas, such as its deteriorating net income, disappointing return on equity, weak operating cash flow, generally disappointing historical performance in the stock itself and feeble growth in its earnings per share. Get the full Stone Energy Ratings Report from TheStreet Quant Ratings now.

EXCLUSIVE OFFER: See inside Jim Cramer's multi-million dollar charitable trust portfolio to see the stocks he thinks could be potential winners. Click here to see his holdings for 14-days FREE.

PetMed Express (PETS) - FREE Research Report

Rosenbloom Bruce S, who is Chief Financial Officer at PetMed Express, sold 500 shares at $16.50 on April 1, 2015. Following this transaction, the Chief Financial Officer owned 45,017 shares meaning that the stake was reduced by 1.1% with the 500-share transaction.

Akdag Menderes, who is CEO & President at PetMed Express, sold 10,000 shares at $16.50 on April 1, 2015. Following this transaction, the CEO & President owned 548,000 shares meaning that the stake was reduced by 1.79% with the 10,000-share transaction.

The shares most recently traded at $16.22, down $0.28, or 1.73% since the insider transaction. Historical insider transactions for PetMed Express go as follows:

  • 4-Week # shares sold: 3,000
  • 12-Week # shares sold: 65,167
  • 24-Week # shares sold: 65,667

The average volume for PetMed Express has been 220,200 shares per day over the past 30 days. PetMed Express has a market cap of $334.7 million and is part of the health care sector and drugs industry. Shares are up 13.08% year-to-date as of the close of trading on Wednesday.

PetMed Express, Inc. and its subsidiaries, doing business as 1-800-PetMeds, operates as a pet pharmacy in the United States. The company markets prescription and non-prescription pet medications, health products, and supplies for dogs and cats. The stock currently has a dividend yield of 4.12%. The company has a P/E ratio of 19.4. Currently, there are no analysts who rate PetMed Express a buy, 2 analysts rate it a sell, and 3 rate it a hold.

Exclusive Offer: Get the latest Stock Analysis on PETS - FREE

TheStreet Quant Ratings rates PetMed Express as a buy. The company's strengths can be seen in multiple areas, such as its solid stock price performance, largely solid financial position with reasonable debt levels by most measures, reasonable valuation levels, good cash flow from operations and growth in earnings per share. We feel these strengths outweigh the fact that the company shows low profit margins. Get the full PetMed Express Ratings Report from TheStreet Quant Ratings now.

EXCLUSIVE OFFER: See inside Jim Cramer's multi-million dollar charitable trust portfolio to see the stocks he thinks could be potential winners. Click here to see his holdings for 14-days FREE.

null